PVLA - Latest News
Palvella Therapeutics, Inc. (PVLA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.43B. Beta to the broader market is -0.12.
The article list below shows the most recent PVLA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PVLA Headlines
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
globenewswire.com - May 15, 2026
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Glo
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
globenewswire.com - May 13, 2026
Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformat
Palvella Therapeutics Q1 Earnings Call Highlights
marketbeat.com - May 8, 2026
Palvella Therapeutics NASDAQ: PVLA said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microc
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 8, 2026
Palvella Therapeutics, Inc.
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com - May 7, 2026
FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expect
How News Affects PVLA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PVLA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PVLA news questions
- What is the latest PVLA news headline?
- The most recent PVLA headline (May 15, 2026) is "Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PVLA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PVLA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PVLA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.